Karin Jirström Selected Research

Polymeric Immunoglobulin Receptors (Polymeric Immunoglobulin Receptor)

4/2014	Expression and prognostic significance of the polymeric immunoglobulin receptor in esophageal and gastric adenocarcinoma.
2/2014	Expression and prognostic significance of the polymeric immunoglobulin receptor in epithelial ovarian cancer.
1/2014	Reduced expression of the polymeric immunoglobulin receptor in pancreatic and periampullary adenocarcinoma signifies tumour progression and poor prognosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karin Jirström Research Topics

Disease

163	Neoplasms (Cancer) 08/2022 - 02/2005
93	Breast Neoplasms (Breast Cancer) 08/2022 - 01/2005
38	Adenocarcinoma 01/2022 - 02/2011
27	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 11/2009
16	Neoplasm Metastasis (Metastasis) 03/2021 - 01/2007
15	Ovarian Neoplasms (Ovarian Cancer) 01/2018 - 06/2010
14	Melanoma (Melanoma, Malignant) 01/2020 - 07/2011
10	Carcinoma (Carcinomatosis) 02/2022 - 01/2007
10	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 10/2014
9	Urinary Bladder Neoplasms (Bladder Cancer) 02/2022 - 04/2013
9	Lymphatic Metastasis 02/2022 - 09/2009
9	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020 - 11/2012
8	Noninfiltrating Intraductal Carcinoma (DCIS) 06/2020 - 11/2010
8	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020 - 07/2013
7	Lung Neoplasms (Lung Cancer) 01/2020 - 04/2010
7	Ovarian Epithelial Carcinoma 01/2018 - 08/2010
6	Microsatellite Instability 01/2022 - 08/2012
6	Carcinogenesis 01/2021 - 03/2010
6	Disease Progression 07/2015 - 05/2010
6	Prostatic Neoplasms (Prostate Cancer) 01/2015 - 01/2007
5	Stomach Neoplasms (Stomach Cancer) 03/2021 - 12/2014
4	Inflammation (Inflammations) 08/2022 - 01/2015
4	Obesity 01/2019 - 09/2008
3	Hypoxia (Hypoxemia) 01/2020 - 05/2006
3	Adenocarcinoma of Lung 01/2020 - 11/2014
2	Tertiary Lymphoid Structures 01/2020 - 01/2020
2	Body Weight (Weight, Body) 01/2019 - 11/2013

Drug/Important Bio-Agent (IBA)

78	Proteins (Proteins, Gene)FDA Link 02/2022 - 02/2005
49	Biomarkers (Surrogate Marker)IBA 02/2022 - 04/2007
29	Estrogen ReceptorsIBA 01/2022 - 07/2005
24	Tamoxifen FDA LinkGeneric 11/2021 - 01/2005
23	Messenger RNA (mRNA)IBA 02/2022 - 11/2006
16	Hormones (Hormone)IBA 11/2020 - 07/2005
12	Cyclin D1IBA 08/2017 - 09/2005
11	Progesterone Receptors (Progesterone Receptor)IBA 01/2020 - 07/2005
10	AntibodiesIBA 01/2018 - 10/2008
9	Estrogens (Estrogen)FDA Link 01/2018 - 05/2007
8	RNA (Ribonucleic Acid)IBA 01/2022 - 11/2006
8	ErbB Receptors (EGF Receptor)IBA 01/2020 - 07/2007
8	podocalyxinIBA 01/2020 - 07/2012
7	Small Interfering RNA (siRNA)IBA 02/2022 - 11/2008
7	Biological ProductsIBA 12/2018 - 04/2007
7	DNA (Deoxyribonucleic Acid)IBA 10/2015 - 04/2007
6	Phenobarbital (Luminal)FDA Link 08/2022 - 10/2008
6	Estrogen Receptor alphaIBA 01/2021 - 05/2006
6	Oxidoreductases (Dehydrogenase)IBA 01/2018 - 01/2008
6	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2018 - 09/2008
6	Hydroxymethylglutaryl CoA Reductases (HMG CoA Reductase)IBA 01/2015 - 01/2008
5	ParaffinIBA 01/2022 - 07/2011
5	Epidermal Growth Factor (EGF)IBA 03/2021 - 01/2016
5	beta CateninIBA 02/2021 - 08/2012
5	Carrier Proteins (Binding Protein)IBA 01/2021 - 07/2011
5	Thyroid Nuclear Factor 1IBA 01/2019 - 07/2013
4	human ERBB2 proteinIBA 08/2020 - 07/2005
4	Complement Inactivating AgentsIBA 01/2020 - 04/2015
4	Keratin-5 (Keratin 5)IBA 01/2019 - 11/2010
4	LigandsIBA 01/2018 - 11/2013
4	Protein Isoforms (Isoforms)IBA 02/2017 - 04/2010
4	Pharmaceutical PreparationsIBA 01/2017 - 08/2006
4	Glycoproteins (Glycoprotein)IBA 01/2016 - 07/2012
4	CytokinesIBA 10/2015 - 09/2011
4	Tumor Biomarkers (Tumor Markers)IBA 01/2013 - 08/2011
3	Cisplatin (Platino)FDA LinkGeneric 02/2022 - 08/2010
3	Formaldehyde (Formol)FDA Link 01/2022 - 08/2016
3	Trastuzumab (Herceptin)FDA Link 01/2020 - 04/2010
3	Transcription Factors (Transcription Factor)IBA 01/2020 - 01/2010
3	AntigensIBA 01/2020 - 01/2009
3	Oral ContraceptivesIBA 01/2018 - 05/2014
3	Coffee FDA Link 01/2018 - 07/2014
3	ChemokinesIBA 10/2016 - 09/2011
3	ezrinIBA 10/2014 - 01/2007
3	Polymeric Immunoglobulin Receptors (Polymeric Immunoglobulin Receptor)IBA 04/2014 - 01/2014
3	RNA-Binding Proteins (RNA-Binding Protein)IBA 09/2011 - 12/2009
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2008 - 02/2005
3	Cyclin EIBA 04/2007 - 11/2005
2	Insulin (Novolin)FDA Link 08/2022 - 01/2017
2	Caveolin 1IBA 08/2022 - 01/2020
2	Gemcitabine FDA Link 02/2022 - 01/2016
2	Insulin-Like Growth Factor Binding ProteinsIBA 11/2021 - 01/2021
2	Junctional Adhesion Molecule AIBA 03/2021 - 02/2021
2	TubulinIBA 01/2021 - 05/2012
2	CholesterolIBA 01/2021 - 04/2015
2	IGF Type 1 Receptor (IGF 1 Receptor)IBA 01/2021 - 02/2017
2	B7-H1 AntigenIBA 01/2019 - 01/2019
2	Immunoglobulins (Immunoglobulin)IBA 01/2019 - 12/2016
2	Programmed Cell Death 1 ReceptorIBA 01/2019 - 01/2018
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2018 - 01/2017
2	3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)IBA 01/2018 - 09/2008

Therapy/Procedure

34	Therapeutics 03/2021 - 08/2006
15	Drug Therapy (Chemotherapy) 02/2022 - 06/2011
10	Neoadjuvant Therapy 01/2022 - 08/2011
10	Radiotherapy 01/2021 - 08/2011
7	Adjuvant Chemotherapy 01/2022 - 09/2009
6	Pancreaticoduodenectomy 01/2018 - 01/2014
5	Immunotherapy 11/2020 - 01/2020
5	Hormone Replacement Therapy (Therapy, Hormone Replacement) 01/2018 - 05/2007
3	Prostatectomy (Retropubic Prostatectomy) 04/2013 - 05/2010
2	Cystectomy 02/2022 - 01/2019
2	Chemoradiotherapy 01/2019 - 09/2017
2	Segmental Mastectomy (Lumpectomy) 12/2018 - 11/2014